P. Baroldi

发表

Clinical assessment of drug–drug interactions of tasimelteon, a novel dual melatonin receptor agonist

B. Ogilvie, W. Kramer, R. Torres, 2015, Journal of clinical pharmacology.

Venous blood platelets decrease during allergen‐induced asthmatic reactions

L. Fabbri, P. Boschetto, P. Maestrelli, 1990, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Immunoblockade by a specific tachykinin antiserum of the non-cholinergic contractile responses in the guinea-pig isolated bronchus.

C. Maggi, E. Theodorsson, A. Meli, 1990, Journal of autonomic pharmacology.

Inhibition of basal and metoclopramide-induced prolactin release by cabergoline, an extremely long-acting dopaminergic drug.

A. Pontiroli, G. Pozza, P. Baroldi, 1987, The Journal of clinical endocrinology and metabolism.

A phase 2a randomized, parallel group, dose-ranging study of molindone in children with attention-deficit/hyperactivity disorder and persistent, serious conduct problems.

B. K. Taneja, R. Findling, P. Baroldi, 2012, Journal of child and adolescent psychopharmacology.

Relief of pain following intravesical capsaicin in patients with hypersensitive disorders of the lower urinary tract.

C. Maggi, D. Turini, P. Baroldi, 1993, British journal of urology.

Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.

P. Baroldi, A. Paracchi, C. Ferrari, 1988, The Journal of clinical endocrinology and metabolism.

Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women.

A. Paoletti, P. Fioretti, G. Melis, 1987, The Journal of clinical endocrinology and metabolism.

Autoradiographic localization of octylonium bromide binding sites in the rat gastrointestinal tract.

F. Amenta, A. Meli, F. Ferrante, 1991, Archives internationales de pharmacodynamie et de therapie.

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir

A. D. Rodrigues, J. Leonard, A. Hsu, 1997, Antimicrobial agents and chemotherapy.

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir *

J. Leonard, A. Hsu, G. Granneman, 1998, Clinical pharmacology and therapeutics.

Evaluation of personality as a component of the healthy condition of volunteers participating in phase I studies

L. Squassante, D. Berto, S. Milleri, 1996, European Journal of Clinical Pharmacology.

Pharmacokinetics of the Dual Melatonin Receptor Agonist Tasimelteon in Subjects With Hepatic or Renal Impairment

W. Kramer, R. Torres, P. Baroldi, 2015, Journal of clinical pharmacology.

A Pharmacokinetic (PK)-Pharmacodynamic (PD) Relationship Exists for Efficacy of Iloperidone, a Novel Investigational Atypical Antipsychotic Agent

C. Wolfgang, P. Baroldi, D. Fisher, 2007 .

Long‐term efficacy and safety of adjunctive extended‐release oxcarbazepine (Oxtellar XR®) in adults with partial‐onset seizures

P. Baroldi, S. Chung, J. K. Johnson, 2015, Acta neurologica Scandinavica.

Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial

J. French, Jk Johnson, P. Baroldi, 2013, Acta neurologica Scandinavica.

Absolute Bioavailability of Tasimelteon

W. Kramer, R. Torres, M. Dressman, 2015, American Journal of Therapeutics.

A Study of Plasma Disposition Kinetics of Lacidipine After Single Oral Ascending Doses

L. Squassante, M. Pellegatti, S. Braggio, 1994, Journal of cardiovascular pharmacology.